resiquimod has been researched along with pentoxifylline in 2 studies
| Studies (resiquimod) | Trials (resiquimod) | Recent Studies (post-2010) (resiquimod) | Studies (pentoxifylline) | Trials (pentoxifylline) | Recent Studies (post-2010) (pentoxifylline) |
|---|---|---|---|---|---|
| 465 | 14 | 318 | 4,437 | 657 | 943 |
| Protein | Taxonomy | resiquimod (IC50) | pentoxifylline (IC50) |
|---|---|---|---|
| Acetylcholinesterase | Homo sapiens (human) | 6.6 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Dowling, DJ; Kennady, G; Levy, O; Ozog, LS; Speer, EM; Xu, J; Yang, J | 1 |
2 other study(ies) available for resiquimod and pentoxifylline
| Article | Year |
|---|---|
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Pentoxifylline inhibits TLR- and inflammasome-mediated in vitro inflammatory cytokine production in human blood with greater efficacy and potency in newborns.
Topics: Adenosine Triphosphate; Adult; Age Factors; Anti-Inflammatory Agents; Biomarkers; Dose-Response Relationship, Drug; Fetal Blood; Humans; Imidazoles; Infant, Newborn; Inflammasomes; Inflammation Mediators; Interleukin-10; Interleukin-1beta; Interleukin-6; Lipopolysaccharides; Pentoxifylline; RNA, Messenger; Time Factors; Toll-Like Receptors; Tumor Necrosis Factor-alpha | 2017 |